Salud financiera de hoja de balance de Bicycle Therapeutics
Salud financiera controles de criterios 5/6
Bicycle Therapeutics tiene un patrimonio de los accionistas total de $370.9M y una deuda total de $30.7M, lo que sitúa su ratio deuda-patrimonio en 8.3%. Sus activos y pasivos totales son $595.3M y $224.4M respectivamente.
Información clave
8.3%
Ratio deuda-patrimonio
US$30.70m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$526.42m |
| Patrimonio | US$370.93m |
| Total pasivo | US$224.41m |
| Activos totales | US$595.34m |
Actualizaciones recientes sobre salud financiera
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Recent updates
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year
Jan 19Bicycle Therapeutics gives out pipeline update, shares rise
Jan 14What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?
Dec 15Bicycle Therapeutics settles IP dispute with Pepscan
Nov 30Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($561.9M) de BCYC superan a sus pasivos a corto plazo ($69.5M).
Pasivo a largo plazo: Los activos a corto plazo de BCYC ($561.9M) superan a sus pasivos a largo plazo ($154.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BCYC tiene más efectivo que su deuda total.
Reducción de la deuda: BCYC's debt to equity ratio has increased from 0% to 8.3% over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: BCYC tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: BCYC dispone de suficiente cash runway para 2.2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 30.5% cada año.